Patients with ulcerative colitis (UC) have an increased risk of developing colorectal cancer (CRC). A meta-analysis by Eaden et al. [1] that included 116 studies determined an overall prevalence of CRC in any UC patients of 3.7% and cumulative probabilities of CRC of 2% by 10 years, 8% by 20 years, and 18% by 30 years of UC duration. It also observed a geographic variability in CRC incidence rates from 5/1,000 person-years duration in the US, 4/1,000 person-years duration in UK and 2/1,000 person-years duration in Scandinavia and other countries [1] . Several other factors have also been suggested to influence the risk of CRC in patients with UC. A population-based cohort study by Anders Ekbom and his group from Sweden observed an increased risk of CRC in association with more anatomically extensive UC [2] . Patients with pancolitis (SIR 14.8,) and left-sided colitis (SIR 2.8, 95% CI 1.6-4.4) had a 15-fold and threefold increase in standardized incidence ratio, respectively, whereas those with UC limited to the rectum had lower risk of CRC (SIR 1.7, 95% CI 0.8-3.2) [2] . Another report from a combined Swedish and English population cohort observed a significantly increased 19.2 excess risk of CRC in those with pancolitis (p = 0.001) and 3.6 (p = 0.01) in those with left-sided colitis [3] . Younger age at the onset of UC was also found to significantly impact the risk of CRC based on data from population-based cohort [2] . Patients younger than 15 years at the time of UC diagnosis had the highest risk of CRC (SIR 118.3, 95% CI 63.0-202.3) [2] . An absolute risk of CRC was 40% in patients younger than 15 years of age at the time of initial UC diagnosis, 25% for those aged 15-39 years, and 15% for those aged more than 40 years [2] . Multivariable logistic regression identified that among analyzed variables, age at the time of UC diagnosis, extent of UC at diagnosis, and duration of follow-up only age younger than 15 years (adjusted SIR 4.03, 95% CI 2.07-7.85) and presence of pancolitis (adjusted SIR 5.27, 95% CI 3.22-8.61) at the time of initial UC diagnosis were significantly associated with four-fivefold increased risk of CRC [2] . The risk of CRC adjusted for extent of disease at the time of initial diagnosis decreased with each increase in age group at diagnosis (age \15, 15-29, 30-39, 40-49, 50-59, and 60 years and above) [2] . An analysis of the cohort from an academic referral center determined that severity of histologic inflammation within the colon of UC patients increases the risk of CRC threefold (HR 3.0, 95% CI 1.4-6.3) [4] . Data from tertiary referral center casecontrol study found that increasing severity of both endoscopically visible and histological colonic inflammation are associated with 2.5-fold (OR 2.5, 95% CI 1.45-4.44) and fivefold (5.13, 95% CI 2.36-11.14) increased risk of CRC among UC patients when compared to non-CRC UC controls, respectively [5] .
Patients with ulcerative colitis (UC) have an increased risk of developing colorectal cancer (CRC). A meta-analysis by Eaden et al. [1] that included 116 studies determined an overall prevalence of CRC in any UC patients of 3.7% and cumulative probabilities of CRC of 2% by 10 years, 8% by 20 years, and 18% by 30 years of UC duration. It also observed a geographic variability in CRC incidence rates from 5/1,000 person-years duration in the US, 4/1,000 person-years duration in UK and 2/1,000 person-years duration in Scandinavia and other countries [1] . Several other factors have also been suggested to influence the risk of CRC in patients with UC. A population-based cohort study by Anders Ekbom and his group from Sweden observed an increased risk of CRC in association with more anatomically extensive UC [2] . Patients with pancolitis (SIR 14.8, 95% ) and left-sided colitis (SIR 2.8, 95% CI 1.6-4.4) had a 15-fold and threefold increase in standardized incidence ratio, respectively, whereas those with UC limited to the rectum had lower risk of CRC (SIR 1.7, 95% CI 0.8-3.2) [2] . Another report from a combined Swedish and English population cohort observed a significantly increased 19.2 excess risk of CRC in those with pancolitis (p = 0.001) and 3.6 (p = 0.01) in those with left-sided colitis [3] . Younger age at the onset of UC was also found to significantly impact the risk of CRC based on data from population-based cohort [2] . Patients younger than 15 years at the time of UC diagnosis had the highest risk of CRC (SIR 118.3, 95% CI 63.0-202.3) [2] . An absolute risk of CRC was 40% in patients younger than 15 years of age at the time of initial UC diagnosis, 25% for those aged 15-39 years, and 15% for those aged more than 40 years [2] . Multivariable logistic regression identified that among analyzed variables, age at the time of UC diagnosis, extent of UC at diagnosis, and duration of follow-up only age younger than 15 years (adjusted SIR 4.03, 95% CI 2.07-7.85) and presence of pancolitis (adjusted SIR 5.27, 95% CI 3. 22-8.61 ) at the time of initial UC diagnosis were significantly associated with four-fivefold increased risk of CRC [2] . The risk of CRC adjusted for extent of disease at the time of initial diagnosis decreased with each increase in age group at diagnosis (age \15, 15-29, 30-39, 40-49, 50-59, and 60 years and above) [2] . An analysis of the cohort from an academic referral center determined that severity of histologic inflammation within the colon of UC patients increases the risk of CRC threefold (HR 3.0, 95% CI 1.4-6.3) [4] . Data from tertiary referral center casecontrol study found that increasing severity of both endoscopically visible and histological colonic inflammation are associated with 2.5-fold (OR 2.5, 95% CI 1.45-4.44) and fivefold (5.13, 95% CI 2.36-11.14) increased risk of CRC among UC patients when compared to non-CRC UC controls, respectively [5] .
Another important risk factor for CRC observed in population-based studies in patients with UC was a family history of CRC in a first-degree relative. Patients with UC and family history of CRC were found to have twofold increased risk of CRC than those with negative family history of CRC (RR 2.0, 95% CI 1.0-4.1) [6] . On the other hand, family history of IBD was not associated with an increased risk of CRC in patients with UC (RR 1.2, 95% CI 0.6-2.4 [6] and RR 1.91, 95% CI 0.62-3.22 [7] ). Metaanalysis of 11 referral center-based studies observed that patients with UC and primary sclerosing cholangitis (PSC) determined that presence of PSC increases risk of CRC fourfold when compared to patients with UC alone (OR 4.09, 95% CI 2.89-5.76) [8] .
Finally, Velayos et al. [9] identified factors that are associated with CRC risk in patients with UC. Multivariable analysis of data obtained retrospectively from 188 patients with UC and CRC and non-CRC UC controls seen at Mayo Clinic, Rochester, MN, USA, identified that a family history of CRC (OR 3.7, 95% CI 1.0-13.2) and history of pseudopolyps (OR 2.5, 95% CI 1.4-4.6) were associated with significantly increased CRC risk whereas having at least one surveillance colonoscopy (OR 0.4, 95% 0.2-0.7), smoking after diagnosis of UC (OR 0.5, 95% CI 0.2-0.9), use of corticosteroids more than 1 year (OR 0.4, 95% CI 0.2-0.9), mesalamine no longer than 1-5 years (OR 0.4, 95% CI 0.2-0.9), aspirin (OR 0.3, 95% CI 0.1-0.8), and non-steroidal anti-inflammatory drugs (OR 0.1, 95% CI 0.03-0.5) were associated with a decreased risk of CRC [9] . An analysis of data obtained from Hungarian population-based cohort of patients with UC determined that duration of UC[10 years (OR 8.33, 95% CI 1.10-68.9), more extensive UC (OR 1.76, 95% CI 1.01-03.07), presence of PSC (OR 9.50, 95% CI 2.23-40.5) and colonic dysplasia on biopsy before diagnosis of CRC (OR 4.72, 95% CI 1.00-22.3) significantly increased the risk of CRC [10] . A recent population-based study by Shaukat et al. [11] identified that UC increases risk of CRC twofold in patients aged C67 years (OR 1.93; 95% CI 1.54-2.49).
Current guidelines issued by the American Gastroenterological Association recommend that all patients with UC should undergo screening colonoscopy within 8 years from the beginning of UC symptoms with multiple biopsies obtained from the entire colon in order to assess the extent of disease [12] . Surveillance colonoscopy should be performed within 1-2 years from screening colonoscopy in patients with pancolitis or left-sided colitis [12] . If two consecutive colonoscopies do not identify colonic dysplasia or CRC, subsequent colonoscopies should be done every 1-3 years [12] . The presence of certain CRC risk factors in UC patients influences the management of surveillance colonoscopies [12] . In patients with UC and PSC, surveillance colonoscopy is recommended upon diagnosing PSC with further colonoscopies on annual basis [12] . More frequent surveillance colonoscopies are also recommended in patients with a family history of CRC, presence of active endoscopic or histologic inflammation within colon, colonic anatomic abnormalities, or multiple inflammatory pseudopolyps [12] . The most preferred CRC screening strategy in the general population with an average risk of CRC includes colonoscopy as CRC prevention test that is recommended every 10 years beginning at the age of 50 years (in African Americans at the age of 45 years) [13] .
In this issue of the journal, Shaukat et al. [14] present their results of a population-based study in which they assessed and compared CRC survival between elderly patients (C67 years) with and without UC. The data from the years 1993 to 1999 were retrieved using the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER)-Medicare linkage program [14] . Among 47,543 patients with CRC (155 patients with CRC and UC), CRC was diagnosed at a younger age (42 vs. 35% for age 67-74, p = 0.04 and 16 vs. 21% for age C85; p = 0.04) and earlier stages (42 vs. 37%, p = 0.04 (TNM stages 1 and 2) and 11 vs. 17%, p = 0.04 (TNM stage 4) in patients with UC when compared to non-UC population [14] . Multivariable logistic regression analysis determined that male sex, age C75 years upon CRC diagnosis, African American ethnicity, and more advanced TNM stage at CRC diagnosis were associated with a significantly 1.2-7.7-fold increased risk of death from CRC within 3 years whereas diagnosis of UC and location of CRC were not [14] . Although unadjusted Kaplan-Meier comparison demonstrated the trend towards greater 3-year survival in CRC patients with UC versus non-UC (p = 0.03), stratification by the CRC stage at the time of CRC diagnosis showed similar 3-year survival within given CRC stage between UC and non-UC patients [14] .
Several studies have assessed an association between CRC and UC and outcomes of CRC in UC and non-UC patients, though these studies did not focus exclusively on elderly population with age at the time of CRC diagnosis ranging between 17 and 86 years. A retrospective analysis of 290 IBD-CRC and 290 sporadic CRC patients' records seen at Mayo Clinic between 1976 and 1996 demonstrated similar 5-year survival rates (54 vs. 53%, p = 0.94) [15] . Likewise, another tertiary-referral center-based study from Cleveland Clinic observed similar 5-year survival rates between 240 IBD-CRC and 480 sporadic CRC patients who underwent CRC-related surgery between 1980 and 2007 (77 vs. 72%, p = 0.5) [16] . On the other hand, data from two population-based studies have suggested that IBD worsens the prognosis of CRC. An analysis of data of 71,538 patients diagnosed with CRC (279 patients with UC) between 1977 and 1999, and obtained from the Danish Cancer Registry and the Danish Hospital Discharge Registry demonstrated significantly increased mortality rate ratios within 1 year (1.24 (95% CI 1.02-1.51) and 5 years (1.17 (95% CI 1.01-1.36) from CRC diagnosis in patients with UC when compared to those without UC [17] . The negative effect of UC on CRC survival was augmented in patients with UC duration of more than 8 years, younger (\59 years) age at CRC diagnosis, and more advanced or unknown CRC stage [17] . There was similar distribution of CRC stage between UC and non-UC patients (localized cancer 46.6 vs. 44%, regional spread 30.1 vs. 28.3%, and distant metastasis 16.5 vs. 19.4%) [17] . Another population-based study from Sweden analyzed 2,462 cancer patients with IBD and 1,011,894 cancer patients without IBD that were identified in the cancer registry 1964 and 2006 [18] . Patients with IBD had significantly higher risk of death from CRC than non-IBD patients (colon cancer: HR 1.51; 95% CI: 1.20-1.90 and rectal cancer: HR 1.48; 95% CI: 1.04-2.10) [18] . Younger age (\60 years) at CRC diagnosis and male sex were associated with a higher 1.5-1.7 increased mortality risk in IBD than non-IBD patients [18] . On the other hand, no difference in CRC staging detected between IBD and non-IBD patients [18] .
Cochrane Collaboration analysis of data pooled from three case-control studies showed no difference in CRCrelated death between UC patients who underwent surveillance colonoscopies and those who did not (RR 0.81, 95% CI 0.17-3.83) [19] . However, these studies had either a low number of patients with UC-CRC or those who participated in colonoscopy surveillance programs. A recent study by Lutgents et al. [20] claimed that surveillance colonoscopy improves survival among patients with IBD-CRC. Among 149 patients who were diagnosed with IBD-CRC between 1990 and 2006 in eight Dutch university centers, 23 underwent colonoscopic surveillance and these patients had significantly greater 5-year survival rates when compared to those who did not undergo surveillance (100 vs. 74%, p = 0.042) [20] . In addition, more patients with early stages (TNM 0 or 1) of CRC were found in surveillance than non-surveillance group (52 vs. 24%, p = 0.004) [20] .
The findings of Shaukat et al. [14] that UC does not worsen CRC survival are consistent with data from the Mayo Clinic [15] and the Cleveland Clinic [16] . Of note, Shaukat et al. [14] focused exclusively on the potential impact of UC on the CRC survival in elderly patients. Patients with UC undergo colonoscopic surveillance for CRC earlier than those patients in the general population, thus it is expected that UC patients would be diagnosed with CRC at an earlier stage and at a younger age more likely than patients in the general population. On the other hand, findings by Shaukat et al. [14] differ from data from the Scandinavian population-based studies that found a worsened survival among IBD-CRC patients [17, 18] . As Shaukat et al. realized, this might be explained by the fact that these studies included patients diagnosed with CRC as far back as 1966 [18] and 1977 [17] when colonoscopic surveillance was not widely implemented. In addition, the Swedish study included patients with both UC and Crohn's disease, which might have affected the outcome [18] .
Moreover, there might have been differences in the surveillance protocols between Scandinavia and the US. Finally, Shaukat et al. [14] focused solely on patients at least 67 years old.
The authors are to be congratulated on their effort to determine the impact of UC on CRC survival. This is a very important subject as an association between UC and CRC survival is controversial and the data from elderly population-based cohort studies have not been available thus far.
There are, however, several concerns that need to be addressed. First, no prior studies have indicated improved survival among UC patients with CRC when compared to those with sporadic CRC, as Shaukat et al. [14] suggested. Studies by Karlen et al. [21] and Choi et al. [22] determined that colonoscopic surveillance is associated with an improved CRC survival in patients with UC when compared to UC patients not undergoing colonoscopic surveillance. These studies did not compare CRC survival in UC patients versus patients in the general population. As discussed above, these studies [21, 22] along with a study by Lashner et al. [23] were included in a Cochrane Collaboration analysis [19] that found no survival benefit in UC-CRC patients who underwent colonoscopic surveillance versus those who did not. Second, Shaukat et al. assessed only 3-year CRC survival, whereas previous studies reported 5-year survival. Additional limitation might be the fact that elderly patients are more likely to have other co-morbidities that may have caused their death earlier than CRC would have caused them to die and thus similar survival between UC and CRC and sporadic CRC might be confounded. Third, Shaukat et al. did not take into consideration in their analysis factors that increase CRC in patients with UC such as PSC, a family history of CRC, duration of disease or extent of disease, the presence of pseudopolyps, or medications used. Fourth, relatively small numbers of patients within subgroups with various CRC TNM stages could have potentially influenced statistical analysis. Fifth, pathologic data on the colectomies performed in population cohort studies were not available.
In summary, this is a very important study indicating similar survival between elderly patients with UC-CRC and sporadic CRC. However, further prospective population-based studies are needed to address the concerns that have been raised herein.
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